ILC - Institut inter-régionaL de Cancérologie

What ILC - Institut inter-régionaL de Cancérologie does

ILC (Institut inter-régionaL de Cancérologie), operating under the legal entity GIE VEGA, is a French regional oncology network delivering radiotherapy, chemotherapy, targeted therapies, and radiosurgery across five specialized centers: Centre Jean Bernard (Le Mans), Centre Mallet Proux (Laval), COREL (Chartres), Centre d'Oncologie de Gentilly, and the joint Centre de Cancérologie de la Sarthe opened in 2023. The group employs 22 physicians (18 radiation oncologists and 4 medical oncologists) and more than 250 healthcare professionals, serving cancer patients referred by general practitioners and specialists within the French public healthcare system.

Treatment is delivered via a fleet of high-precision particle accelerators — Varian TrueBeam, Halcyon, and CyberKnife systems — enabling stereotactic radiosurgery, extracranial stereotactic radiotherapy for oligometastatic cancers, real-time image-guided radiotherapy, and conventional fractionated courses. The group operates two clinical research structures, SORECOH at Centre Jean Bernard and ORACLE at Centre d'Oncologie de Gentilly, supporting trial participation and protocol development. A 2023 public-private partnership with Centre Hospitalier du Mans and Clinique Victor Hugo consolidates cancer care on a single Le Mans site, and a medical cooperation agreement with CHU Angers extends CyberKnife radiosurgery across eastern Pays de la Loire.

The revenue model is professional services reimbursement under the French social security system; all centers operate as Sector 1 conventioned facilities with no fee overruns beyond the regulated tariff. Patient acquisition is referral-driven from GPs and specialists, with no direct-to-consumer marketing. The group is physician-led under a GIE (Groupement d'Intérêt Économique) ownership structure with no disclosed external institutional investors, and ongoing CapEx (TrueBeam rollouts at COREL and Mallet Proux) signals continued reinvestment into equipment and capacity.

Name

ILC - Institut inter-régionaL de Cancérologie

Legal name

GIE VEGA

Website

https://i-l-c.fr

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

ILC is a French regional oncology network operating five cancer treatment centers across Sarthe, Mayenne, Eure-et-Loir, and Meurthe-et-Moselle, delivering radiotherapy, chemotherapy, targeted therapy, and CyberKnife radiosurgery to cancer patients via the French public healthcare system.

Ownership category

akta.pro rank

Product category

Oncology Services

NAICS

Ambulatory Health Care Services (621), Offices of Physicians (62111)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

Keywords

• Cancer treatment services
• Radiotherapy centers
• Chemotherapy services
• Oncology consultations
• Clinical research oncology

Headquarters

HQ city

Le Mans, Pays de la Loire

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Others

Revenue model

1. Healthcare Services Revenue: Revenue generated from radiotherapy, chemotherapy, targeted therapy, and medical consultations for cancer patients. Services are covered by French social security system as a Sector 1 conventioned facility with no additional charges to patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ILC operates a network of cancer treatment centers in France, providing radiotherapy, chemotherapy, targeted therapies, and medical oncology consultations. The organization is legally structured as GIE VEGA (Groupement d'Intérêt Économique), a private healthcare group treating patients under the French sector 1 conventioned pricing system across five specialized sites.

Product overview

ILC (Institut inter-régionaL de Cancérologie) is a regional cancer treatment group operating multiple specialized oncology centers: Centre Jean Bernard (Le Mans), Centre Mallet Proux (Laval), COREL (Chartres), and Centre d'Oncologie de Gentilly. The group offers an integrated portfolio of cancer treatment services including radiotherapy (using TrueBeam, Halcyon accelerators and Cyberknife technology), chemotherapy, and targeted therapies, complemented by external consultations and clinical research divisions (SORECOH and ORACLE). The centers provide advanced radiotherapy techniques including extra-cranial stereotactic radiotherapy and radiochirurgie. Recent equipment upgrades include TrueBeam accelerators installed at COREL (2025) and Mallet Proux (2026), and Cyberknife radiochirurgie capability at Centre Jean Bernard (2023).

Differentiator

Problem solved

Functional benefit

Brands

• Centre Jean Bernard: Flagship ILC cancer treatment center in Le Mans, also serving as the future headquarters of ILC Group and the new Centre de Cancérologie de la Sarthe.
• Centre Mallet Proux
• COREL (Centre d'Oncologie d'Eure-et-Loir)
• Centre d'Oncologie de Gentilly
• Centre de Cancérologie de la Sarthe
• SORECOH
• ORACLE (Organisation, Recherche et Avancées en Cancérologie Libérale de l'Est)

Products and services

• Radiotherapy Treatment
• Chemotherapy Treatment
• Targeted Therapies
• Medical Oncology Consultations
• Clinical Research and Trials

Quantifiable outcome

• 50+ patients treated with stereotactic extracranial radiotherapy since implementation
• +2 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Centre de Cancérologie de la Sarthe (Clinique Victor Hugo, Centre Jean Bernard ILC, Centre Hospitalier du Mans)coreStrategic or Co-development Partner · 6 October 2023Unprecedented public-private partnership grouping three major healthcare establishments on a single site. The Centre de Cancérologie de la Sarthe opened in early 2023 and was inaugurated on October 6, 2023. This partnership strengthens local medical offerings for cancer care in the Sarthe region, combining private (ILC, Clinique Victor Hugo) and public (Centre Hospitalier du Mans) healthcare providers.
• Centre Hospitalier Universitaire d'AngerscoreStrategic or Co-development Partner · 1 January 2023Medical cooperation agreement for developing radiosurgery using CyberKnife for treatment of neurological pathologies of tumorous, vascular, or functional origin. The partnership enables access to innovative treatment for patients in the eastern half of the Pays de la Loire region. Neurochirurgiens and radiation oncologists review each case collegially.
• City of Le MansminorStrategic or Co-development PartnerJoint investor in CyberKnife radiosurgery equipment in 2023.
• Department of SartheminorStrategic or Co-development PartnerJoint investor in CyberKnife radiosurgery equipment in 2023.
• Région des Pays de la LoireminorStrategic or Co-development PartnerJoint investor in CyberKnife radiosurgery equipment in 2023.
• La SORECOH (Société de Recherche Clinique en Oncologie et Hématologie)coreStrategic or Co-development PartnerClinical research society in oncology and hematology operating within Centre Jean Bernard. Committed to following Good Clinical Practice rules. Collaborates on clinical trials with trained professionals including oncologists, clinical research associates, laboratory technicians, pharmacists, preparers, and nurses.
• ORACLE (Organisation, Recherche et Avancées en Cancérologie Libérale de l'Est)coreStrategic or Co-development PartnerClinical research structure within Centre d'Oncologie de Gentilly, created in April 2005. Vocation to facilitate clinical research implementation in oncology and develop new cancer treatment techniques. Committed to following Good Clinical Practice rules.
• Hôpital Pasteur (Chartres)minorStrategic or Co-development PartnerClinical research conducted jointly with Hôpital Pasteur. Practitioners provide indications when patients are concerned.
• Polyclinique du MaineminorStrategic or Co-development PartnerChemotherapy treatments performed at Polyclinique du Maine for Mallet Proux patients. Includes day hospital (2 beds, 4 chairs) and traditional hospitalization (25 beds). Supportive care services provided in coordination.

Scale indicators5 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Centre Oscar Lambret: CLCC in Lille delivering radiotherapy, chemotherapy, and oncology research in northern France. Comparable regional oncology provider with similar service mix and academic/research integration.
• Institut Curie: Paris-based comprehensive cancer center with three sites delivering radiotherapy, chemotherapy, and translational research. Comparable to ILC in offering full-spectrum cancer treatment plus clinical research; broader geographic reach and academic standing set it apart.
• Institut Paoli-Calmettes: CLCC in Marseille providing comprehensive cancer care including radiotherapy, chemotherapy, and clinical trials. Comparable in modality and research integration; operates in a different French region.
• Centre Léon Bérard: CLCC (Comprehensive Cancer Center) in Lyon specializing in radiotherapy, chemotherapy, and oncology research. Comparable as a French regional oncology provider with similar modality mix; ILC's CyberKnife and stereotactic offering competes with CLCC's advanced radiotherapy capabilities.
• Gustave Roussy: Largest European cancer center in Villejuif/Paris region offering advanced radiotherapy (including stereotactic), chemotherapy, and clinical trials. Comparable to ILC in modality breadth and research activity; vastly larger scale.
• Institut de Cancérologie de l'Ouest (ICO): French regional cancer center network operating two sites (Angers, Nantes) in the Pays de la Loire region. Directly comparable to ILC as a multi-site private/non-profit oncology network offering radiotherapy, chemotherapy, and clinical research; ICU's scale and academic hospital affiliations make it a primary regional competitor to ILC's Mallet Proux and Sarthe sites.

Broad incumbents

• Unicancer: Federation of 18 French Comprehensive Cancer Centers (CLCCs). Indirectly comparable as the dominant organized network for French cancer care; ILC operates outside this federation, but Unicancer sets competitive benchmarks and shapes national oncology policy.

Regional players

• Centre François Baclesse: CLCC in Caen (Normandy) delivering comprehensive cancer care including advanced radiotherapy and clinical research. Comparable to ILC as a regional oncology network, though operating under the Unicancer federation.
• Centre Henri Becquerel: CLCC in Rouen (Normandy) offering radiotherapy, chemotherapy, and oncology research. Comparable regional oncology provider with similar modality mix; geographically adjacent to some ILC catchment areas.

Others

• ELSAN (Clinique Victor Hugo): Leading French private hospital group; partner of ILC in the Centre de Cancérologie de la Sarthe partnership. Comparable as a private healthcare delivery operator but operates more broadly across specialties; relevant as a partner/peer in private oncology delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/institut-inter-r%C3%A9gional-de-canc%C3%A9rologie

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ILC - Institut inter-régionaL de Cancérologie